Dual paraneoplastic syndromes in a patient with small cell lung cancer: a case report by Coners, Kristin et al.
CASE REPORT Open Access
Dual paraneoplastic syndromes in a patient with
small cell lung cancer: a case report
Kristin Coners, Scott E Woods
* and Michael Webb
Abstract
Introduction: We describe the case of a patient with small cell lung cancer and dual paraneoplastic syndromes
involving adrenocorticotropic hormone and calcitonin. To the best of our knowledge, dual paraneoplastic
syndromes involving these two hormones have not been previously reported in the literature.
Case presentation: A 74-year-old Caucasian woman presented with a left hilar mass and metastatic disease in the
liver and right adrenal gland. The patient complained only of intermittent diarrhea. Her laboratory values exhibited
metabolic alkalosis with hypokalemia, hypocalcemia, hypomagnesemia, hypophosphatemia, and hyperglycemia.
Conclusion: We discuss the work-up and treatment of the patient’s unusual laboratory presentation with two
concurrent paraneoplastic syndromes.
Introduction
Although paraneoplastic syndromes occur commonly,
dual paraneoplastic syndromes occurring simultaneously
in the same patient are very rare. We describe the case
of a patient with small cell lung cancer and dual para-
neoplastic syndromes involving adrenocorticotropic hor-
mone and calcitonin.
Case report
A 74-year-old Caucasian woman presented to the Emer-
gency Department (ED) at our hospital with acute onset
of thoracic back pain. Her medical history included
hypertension, hypothyroidism, a right hip replacement,
and diffuse large cell lymphoma in 1985, which was
treated successfully with chemotherapy and radiation.
She was a previous smoker who had quit approximately
five years earlier. Upon review of her systems, she com-
plained only of some diarrhea that she had experienced
intermittently for one year. Her medications included
atenolol, hydrochlorothiazide, and levothyroxine. Her
vital signs and physical examination in the ED were
remarkable only for thoracic spine tenderness. X-rays
revealed a compression fracture of her T9 vertebra (age
indeterminate) and a new left hilar mass. A renal panel
revealed the following abnormalities: potassium 2.7
mEq/l (lower limit of normal (LLN), 3.5 mEq/l), chloride
74 mEq/l (LLN, 101 mEq/l), bicarbonate 47 mM/l
(upper limit of normal (ULN), 36 mM/l), glucose 198
mg/dl, blood urea nitrogen (BUN) 38 mg/dl (ULN, 20
mg/dl), and creatinine 1.3 md/dl (ULN, 1.2 md/dl), with
normal levels of sodium (137 mEq/l), total calcium (9.1
mg/dl), and magnesium (1.7 mEq/L). A computed
tomography scan showed a left hilar mass with meta-
static disease in the liver and right adrenal gland. There
was no evidence of a pathological fracture of her ninth
thoracic vertebrae.
The patient was admitted to the hospital for hydration
and electrolyte replacement. During her hospital stay,
the patient’s blood sugar was elevated, and she received
insulin coverage. She also received an oral bisphospho-
nate. Additional diagnostic work-up included a stool
culture and testing for Clostridium difficile toxins A and
B, which were negative. Interventional radiology was
performed, and a biopsy of one of the liver lesions was
obtained. The patient was discharged to home five days
after admission with instructions to discontinue hydro-
chlorothiazide and begin taking spironolactone 25 mg
twice daily, alendronate 70 mg weekly, and metformin
500 mg twice daily. Her renal panel at the time of dis-
charge showed significant improvement: sodium 142
mEq/l (normal), potassium 3.3 mEq/l (LLN, 3.5 mEq/l),
chloride 102 mEq/l (normal), bicarbonate 32 mM/l (nor-
mal), glucose 132 mg/dl, BUN 35 mg/dl (ULN, 20 mg/
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any medium, provided the original work is properly cited.dl), creatinine 1.0 md/dl (normal), and total calcium 8.1
mg/dl (LLN, 8.5 mg/dl). She was instructed to follow up
with her oncologist for biopsy results.
The patient re-presented to the ED four days after her
discharge with complaints of worsening diarrhea. Aside
from an elevated blood pressure of 164/76 mmHg, her
physical examination and vital signs were again unre-
markable. Her renal panel now showed sodium 141
mEq/l, potassium 1.9 mEq/l, chloride 95 mEq/l, bicarbo-
nate 30 mM/L, glucose 177 mg/dl, BUN 46 mg/dl, crea-
tinine 1.4 md/dl, total calcium 6.2 mg/dl, ionized
calcium 2.7 mg/dl (LLN, 4.6 mg/dl), magnesium 1 mEq/
L (LLN, 1.4 mEq/L), phosphorous 2.1 mg/dl (LLN, 2.5
mg/dl). The pathology report diagnosed her tumor as
small cell lung cancer (SCLC).
Our residency program admitted the patient for
hydration, electrolyte replacement, and further work-up.
Stool studies including ova and parasites, repeat culture,
and Clostridium difficile toxin were negative. A gastro-
enterologist performed a flexible sigmoidoscopy and
reported that the colonic mucosa appeared normal.
Biopsies showed minimal and focal active inflammation
consistent with focal active colitis of uncertain origin.
The biopsy did not reveal any evidence of architectural
distortion consistent with inflammatory bowel disease or
any evidence of lymphocytic or collagenous colitis.
We conducted serum testing to uncover a possible para-
neoplastic cause for the patient’s symptoms. Her vasoactive
intestine peptide, pancreatic polypeptide, gastrin, serum
aldosterone, plasma renin activity, T4, thyroid-stimulating
hormone, and 1,25-hydroxy vitamin D levels were all
within normal limits. We did discover elevations in the
patient’s calcitonin (81.8 pg/ml; ULN, 4.6 pg/ml) and mid-
night cortisol (80.9 μg/dl; ULN, 10 μg/dl). Her adrenocor-
ticotropin hormone (ACTH) level was 52 pg/ml (normal
range, 6 to 58 pg/ml). We then performed an overnight 8
mg dexamethasone suppression test. The patient’s cortisol
failed to adequately suppress, with pre- and post-test
values of 68.5 μg/dl and 65.5 μg/dl, respectively. Additional
abnormalities included an intact parathyroid hormone
level of 408 pg/ml (ULN, 65 pg/ml) and a 1,25-hydroxy
vitamin D level of 14 ng/ml (LLN, 20 ng/ml).
We treated the patient with oral ketoconazole and
somatostatin (initially every eight hours subcutaneously
and later somatostatin long-acting release intramuscu-
larly). The oncology department also began chemother-
apy with etoposide and carboplatin. The patient’s
diarrhea did improve, as did her laboratory values. Her
calcitonin decreased to 31.3 pg/ml, and her midnight
cortisol fell to 19.4 μg/dl. Unfortunately, the patient’s
condition deteriorated with the initial chemotherapy,
and she chose to discontinue therapy. She was dis-
charged to hospice care.
Discussion
SCLC is the most common cancer histology associated
with paraneoplastic syndromes. Paraneoplastic syn-
dromes are divided into two categories: ectopic produc-
tion of biologically active proteins produced by the
cancer cells and cell-mediated immune responses tar-
geted against neural tissue (Table 1). Patients can pre-
sent with multiple paraneoplastic syndromes at the
same time, especially when the tumor arises from neu-
roendocrine cells. Although rare, there have been
reports in the literature of patients with two or more
paraneoplastic syndromes involving SCLC [1-5]. We
also found a single report of a patient with two sequen-
tial paraneoplastic syndromes concurrently with SCLC
[6]. Our case, however, is the only one reporting SCLC
secreting both ACTH and calcitonin at the same time.
We believe that two paraneoplastic syndromes derived
from SCLC affected this patient (ACTH and calcitonin).
Ectopic ACTH secretion caused new-onset diabetes
mellitus and likely contributed to hypokalemia, meta-
bolic alkalosis, thoracic compression fracture, hyperten-
sion, and emotional liability. Because of a midnight
cortisol level of 80.9 μg/dl and a high index of suspicion,
we bypassed a 24-hour urinary cortisol test and per-
formed an overnight 8 mg dexamethasone suppression
test to determine the source of her hypercortisolism.
The patient’s cortisol level failed to suppress by 68%,
and we made a presumptive diagnosis that her tumor
was secreting ectopic ACTH. Given her high normal
ACTH values, we did attempt to check her ACTH level
by radioimmunoassay to evaluate for the presence of
“big ACTH” particles not identified by immunoradio-
metric assay. Unfortunately, t h el a b o r a t o r ym i s t a k e n l y
ran the wrong study. We also wished to obtain a corti-
cotropin-releasing hormone level, but the patient elected
hospice care prior to this hormone being drawn.
In addition to apparent ectopic ACTH, we further
postulate that ectopic secretion of calcitonin contributed
to the patient’s profuse diarrhea. SCLC secreting calcito-
nin is extremely rare but has been reported [7]. Breast
cancer and medullary thyroid cancer more commonly
secrete calcitonin. The patient’s diarrhea had started one
year prior to her initial presentation and worsened sub-
stantially before her hospital admission. In total, the
patient had four tests for Clostridium difficile, two stool
cultures, and one test for ova and parasites, all of which
were negative. She had a normal endoscopy, and her
pathology report found focal active colitis of unclear
etiology. There was no evidence to suggest inflammatory
bowel disease, and the patient had not been taking med-
ications that would have caused this pathology.
Calcitonin has been known to cause diarrhea in the
spectrum of Verner-Morrison syndrome. We believe
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abnormalities generally seen in patients with this syn-
drome (hypokalemia, achlorhydria, metabolic acidosis,
and hypercalcemia) because of ectopic ACTH secretion
and previous treatment with a bisphosphonate. More
specifically, the patient’s diarrhea should have produced
metabolic acidosis; however, she possessed a metabolic
alkalosis with a δ-gap of 46 caused by excessive cortisol
secretion and dehydration. In addition, the patient’s
hypokalemia was secondary to severe alkalosis, diarrhea,
and excessive cortisol secretion. The patient’s hypocalce-
mia resulted from increased gastrointestinal losses, acute
critical illness, vitamin D deficiency, and renal insuffi-
ciency with secondary hyperparathyroidism.
When surgical therapy is not an option, ketoconazole
is the best therapy for treating patients with SCLC and
ectopic ACTH secretion [8]. Ketoconazole therapy
results in biochemical and hormonal improvement for
most patients with excessive cortisol secretion [9]. It has
few adverse effects, but may impair the cortisol response
to stress. After our patient’s treatment with ketocona-
zole and somatostatin, her diarrhea did improve, as did
her laboratory values. We feel that treatment with keto-
conazole and somatostatin did benefit the patient, given
that chemotherapy had failed to substantially reduce her
tumor burden as demonstrated on subsequent imaging.
SCLC accounts for approximately 15% of all broncho-
genic carcinomas [10]. The average age at diagnosis is
71 years. About 30% of patients with SCLC have lim-
ited-stage disease (cancer limited to one hemithorax and
lymph nodes on the same side of the chest). Patients
w i t hl i m i t e d - s t a g ed i s e a s eh a v eam e d i a ns u r v i v a l
approaching two years and a 14% five-year survival rate.
Patients with extensive disease have a median survival of
less than one year [10]. Patients with SCLC and ectopic
ACTH secretion tend to have more extensive disease
and exhibit less response to chemotherapy, and they are
more likely to die prematurely [11].
Consent
Written informed consent was obtained from the patient
for publication of this case report and any accompany-
ing images. A copy of the written consent is available
for review by the Editor-in-Chief of this journal.
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Table 1 Paraneoplastic syndromes associated with small cell lung cancer
a
Ectopic hormone-associated syndromes Immune-mediated neurologic syndromes
Clinical syndrome Incidence SCLC hormone Incidence Antibody SCLC-expressed gene or protein
Ectopic Cushing’s syndrome 5% ACTH
Hyponatremia of malignancy 15% AVP, CRH (rare)
Hypertension <1% Renin
Amenorrhea, galactorrhea <1% Prolactin, GH
Hyperamylasemia <1% Salivary anylase
Lambert-Eaton myasthenic
syndrome
1% Anti-VGCC Synaptotagmin, MysB
Encephalomyelitis <1% Anti-Hu HuD, HuC, Hel-N1, N2
Sensory neuropathy <1% Anti-Hu HuD, HuC, Hel-N1, N2
Cerebellar degeneration <1% Anti-Hu HuD, HuC, Hel-N1, N2
Anti-VJCC, MysB Synaptotagmin
Anti-Ri Nova-1
Anti-Yo CDR-34
Retinopathy <1% Anti-CAR Recoverin
Stiff-person syndrome
(encephalitis)
<1% Anti-amphiphysin Amphiphysin
Opsoclonus, myoclonus <1% Anti-Hu HuD, HuC, Hel-N1, N2
Anti-Ri Nova-1
HuD, HuC, Hel-N1, N2
Synaptotagmin
Nova-1
aSCLC, small cell lung cancer; ACTH, adrenocorticotropin hormone; AVP, arginine vasopressin; CRH, corticotropin-releasing hormone; GH, growth hormone; VGCC,
voltage-gated calcium channel; MysB,; HuD, Human Neuronal Protein D; HuC, Human Neuronal Protein C; Hel-N1,; VJCC,; Ri,; Yo,; CDR-34,; anti-CAR, anti-coxsackie
adenovirus receptor.
Reprinted with permission from Gandhi L, Johnson BE: Paraneoplastic syndromes associated with small cell lung cancer. J Natl Compr Canc Netw 2006, 4:631-638
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